Generic Name and Formulations:
Capreomycin (as sulfate) 1g/vial; pwd for IV infusion after reconstitution and dilution, or IM inj after reconstitution.
Indications for CAPASTAT:
Adjunct in susceptible tuberculosis when first-line agents (INH, rifampin, ethambutol, aminosalicylic acid, streptomycin) are inappropriate.
Give by IV infusion over 1 hour or deep IM inj. 1g (max 20mg/kg) daily for 60–120 days, then 1g (max 20mg/kg) 2–3 times per week; max 20mg/kg per day. Treat for 12–24 months. Renal dysfunction: reduce dose (see full labeling).
Use with extreme caution in patients with renal insufficiency or preexisting auditory impairment. Usage in pregnancy or pediatric.
Renal or auditory impairment. Monitor vestibular and auditory function at baseline and during therapy. Monitor renal function at baseline and during therapy; reduce dose or discontinue if BUN>30mg/dL or if renal function decreases. Monitor hepatic function and serum potassium. Elderly. Pregnancy (Cat.C; teratogenic; see full labeling). Nursing mothers.
Concomitant streptomycin, other parenteral antituberculars: not recommended. Increased toxicity with other neuro/ototoxic drugs (eg, aminoglycosides).
Neurotoxicity (esp. ototoxicity), renal toxicity, leukocytosis, leukopenia, abnormal liver function tests, inj site reactions (eg, pain, induration, bleeding), rash.
Endocrinology Advisor Articles
- FDA Approves Marketing of 2 Devices to Detect Parathyroid Tissue in Real Time
- Long-Term Efficacy and Safety of Dapagliflozin for Type 1 Diabetes
- Diabetes Education Week 2018: Patient Resources for Your Practice
- Cardiometabolic Disease Patterns Related to Race, Ethnicity in Midlife Women
- AHA, ADA Announce Joint Education Initiative to Reduce CVD Deaths in T2D